A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants

Inclusion Criteria: * Diagnosis of metastatic Stage IV NSCLC * At least 1 measurable extra-central nervous system (CNS) lesion * Documented radiographic progression while on continuous treatment with erlotinib monotherapy * Objective clinical benefit from erlotinib treatment as defined by either documented partial or complete response or stable disease ≥6 months or, if most recent erlotinib treatment has been initiated based on documented epidermal growth factor receptor mutation (EGFRmt) status, at least 12 weeks stable disease * Determined to be MET diagnostic positive (+) * Availability of a tumor sample post-erlotinib progression * Eastern Cooperative Oncology Group (ECOG) performance status ≤2 * Have adequate organ function Exclusion Criteria: * Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational product or non-approved use of a drug or device * Have previously been treated with LY2875358 or any other MET-targeting experimental therapeutic * Have a serious concomitant systemic disorder or significant cardiac disease * Have interstitial pneumonia or interstitial fibrosis of the lung or have pleural effusion, pericardial fluids or ascites, requiring drainage every other week or more frequently * Have a history of another malignancy except for basal or squamous cell skin cancer and/or in situ carcinoma of the cervix, or other solid tumors treated curatively and without evidence of recurrence for at least 3 years prior to the study * Have major surgery less than 2 weeks prior initiation of study treatment therapy * Pregnant or lactating women * Have symptomatic CNS metastasis